Jared Whitlock

San Diego

Features Editor at Endpoints News

Features editor @endpts. Reach out privately on Signal: jaredwhitlock.73

Articles

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

3 days ago | endpoints.news | Jared Whitlock

Among five tech sectors, China has the most immediate opportunity to overtake the US in biotechnology. That’s according to a Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
DNA giant Illumina spawned an ecosystem of competitors and customers

1 week ago | endpts.com | Jared Whitlock

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing company unlocked new … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
DNA giant Illumina spawned an ecosystem of competitors and customers

1 week ago | endpoints.news | Jared Whitlock

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing company unlocked new … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Illumina confirms SEC has closed investigation into $8B Grail deal

1 month ago | endpts.com | Jared Whitlock

Illumina on Thursday said the SEC has closed its investigation into the company’s $8 billion purchase of Grail and doesn’t intend to pursue enforcement action …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Illumina forecasts $85M in tariff costs, decrease in China sales

1 month ago | endpts.com | Jared Whitlock

Illumina estimates about $85 million in costs this year related to tariffs on its DNA sequencing products, the company said during its Thursday quarterly earnings …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Exclusive: SEC expected to drop investigation of Illumina's $8B Grail deal

1 month ago | endpts.com | Jared Whitlock

The SEC is expected to drop an investigation into Illumina’s $8 billion acquisition of cancer test developer Grail, Endpoints News has learned. Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
US drugmakers increasingly look abroad for clinical trials as confidence in FDA wavers

1 month ago | endpts.com | Jared Whitlock

Patient Steve Young last year received a cancer immunotherapy as part of a clinical trial at the University College London Hospital. (Photo by Jordan Pettitt/PA Images via Getty Images)
China’s biotech market is staging a comeback that US biotech can only wish for

1 month ago | endpts.com | Jared Whitlock

China’s biopharmaceutical sector is showing signs of revival from its post-pandemic slump, even as its US counterpart remains in a rut. Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
GeneDx to buy Fabric Genomics for up to $51M

1 month ago | endpts.com | Jared Whitlock

GeneDx is slated to buy Fabric Genomics in a bid to speed up the diagnosis of genetic diseases. The diagnostic company said on Wednesday that …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Amid Trump’s research cuts, commission says US risks losing biotech race without $15B investment

2 months ago | endpts.com | Jared Whitlock

A congressional commission is calling for at least a $15 billion federal investment in America’s biotechnology sector, warning that the US could soon be eclipsed …Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.